BioCentury on BioBusiness,
Refocusing Chiasma yields rich Roche deal for oral somatostatin analog
Delivering on the upside
Monday, February 18, 2013
In 2008 the new CEO of Chiasma
Inc. refocused the drug delivery company on product development with an
eye to capturing more of the upside from the investment in its formulation
technology. On Monday this week, the biotech was to announce its first big
deal, partnering with Roche
to develop an oral somatostatin analog formulated with the biotech's Transient
Permeability Enhancer technology.
Roche is receiving exclusive,
worldwide rights to Octreolin octreotide acetate in return for $65 million up
front. The Israeli biotech is eligible for up to $530 in milestones, plus
tiered, double-digit royalties.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2014 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]